1-4 of 4
Jay M. Feingold
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Clinical Trials & Observations
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl
Journal: Blood
Blood (2021) 137 (19): 2634–2645.
https://doi.org/10.1182/blood.2020007512
Published: 2021
Includes: Supplemental data
Journal Articles

Incidence of Sinusoidal Obstruction Syndrome Following Mylotarg (Gemtuzumab Ozogamicin, GO): a Prospective Observational Study in Routine Clinical Practice.

Marti n S Tallman, George B McDonald, Laurie D DeLeve, Eliot Obi-Tabot, Carl Kollmer, Jay M Feingold
Journal: Blood
Blood (2008) 112 (11): 956.
https://doi.org/10.1182/blood.V112.11.956.956
Published: 2008
Journal Articles

Interim Analysis of a Post Marketing All Cases Surveillance Study of Mylotarg in Japan.

Noriko Usui, MD, Jin Takeuchi, MD, Hisashi Sakamaki, MD, Ryuzo Ohno, MD, Michio Suzukawa, MD, Eliot Obi-Tabot, MD, Jay M. Feingold, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 4376.
https://doi.org/10.1182/blood.V110.11.4376.4376
Published: 2007
Journal Articles

A Post-Marketing Surveillance Study of the Safety and Efficiacy of Refacto® (Moroctocog Alfa, B-Domain Deleted Recombinant Factor VIII) (St. Louis-Derived Active Substance in the Treatment and Prevension of Bleeding Episodes in Hemophilia a Patients.

Jay M. Feingold, MD, PhD, Mark P. Smith, MD, Richard Littlewood, MD, Paul Giangrande, MD, ReFacto STL Study Group
Journal: Blood
Blood (2004) 104 (11): 4023.
https://doi.org/10.1182/blood.V104.11.4023.4023
Published: 2004